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Manuscript
Rasha Al-Lamee and colleagues (2 November, 2017)
1
 report that in patients with medically treated 
angina and a severe single-vessel coronary stenosis, PCI did not increase exercise time by more 
than the effect of a placebo procedure. The authors should be commended for performing the first 
blinded trial to address this issue. However, we have concerns that some features of the trial design 
may limit the applicability of the findings to routine clinical practice. 
Current ESC/EACTS guidelines recommend that revascularisation should be performed for 
any coronary stenosis >50% in the presence of limiting angina unresponsive to medical therapy, but 
require documented ischaemia or an FFR ≤0.80 for those with a stenosis <90%2. 
In the ORBITA trial, patients were not required to have documented ischaemia and FFR was 
not used to guide revascularisation. Indeed, 29% of patients had an a FFR >0.80 and would 
therefore not meet current recommendations for revascularisation. Furthermore, following a 6-week 
period of intensive medical therapy optimisation, 9% of PCI patients had no symptoms (CCS Class 
0), mean angina frequency was monthly (SAQ angina frequency score 79) and mean exercise time 
was normal (smoothed Bruce treadmill protocol duration 8:48). For these reasons, it is not 
surprising that PCI failed to show a significant improvement in exercise time, when compared with 
a placebo procedure. 
In our opinion, caution should be exercised before changing practice on the basis of this 
trial. 
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